BIONET Therapeutics Corp. (TPEX:7808)
Taiwan · Delayed Price · Currency is TWD 34.95
-0.05 (-0.14%)
At close: Sep 17, 2026
BIONET Therapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 31.27 | 99.52 | 21.97 | 45.3 | 53.97 |
Short-Term Investments | 945.56 | 936 | 1,155 | 458 | - |
Trading Asset Securities | 54.63 | 24.45 | 37.72 | 21.02 | - |
Cash & Short-Term Investments | 1,031 | 1,060 | 1,215 | 524.32 | 53.97 |
Cash Growth | -9.31% | -12.74% | 131.67% | 871.44% | - |
Accounts Receivable | 28.01 | 27.57 | 15.11 | 1.17 | - |
Other Receivables | 13.97 | 8.23 | 6.59 | 1.6 | - |
Receivables | 41.98 | 35.8 | 21.7 | 2.77 | - |
Inventory | 41.34 | 30.08 | 29.52 | 0.37 | - |
Prepaid Expenses | 9.88 | 11.87 | 8.98 | 0.89 | 0.15 |
Other Current Assets | 0.09 | 0.09 | 0.09 | - | - |
Total Current Assets | 1,125 | 1,138 | 1,275 | 528.35 | 54.12 |
Property, Plant & Equipment | 144.62 | 138.51 | 54.22 | 8.72 | - |
Long-Term Investments | 3.44 | 2.75 | 4.92 | - | - |
Other Intangible Assets | 2.74 | 2.83 | 0.36 | - | - |
Other Long-Term Assets | 2.52 | 1.18 | 15.55 | 3.11 | - |
Total Assets | 1,278 | 1,283 | 1,350 | 540.18 | 54.12 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 11.41 | 7.97 | 16.84 | 5.23 | 0.68 |
Accrued Expenses | 19.63 | 25.8 | 13.56 | 3.39 | 4.65 |
Current Portion of Leases | 5.78 | 1.02 | - | - | - |
Current Unearned Revenue | 24.78 | 11.3 | 4.32 | 2.61 | - |
Other Current Liabilities | 5.57 | 11.68 | 18.98 | 0.86 | 0.09 |
Total Current Liabilities | 67.16 | 57.77 | 53.7 | 12.09 | 5.42 |
Long-Term Leases | 18.17 | 9.88 | - | - | - |
Total Liabilities | 85.33 | 67.65 | 53.7 | 12.09 | 5.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 700 | 700 | 700 | 450.29 | 56 |
Additional Paid-In Capital | 710.2 | 712.7 | 716.29 | 124.86 | - |
Retained Earnings | -262.24 | -231.12 | -133.7 | -47.44 | -7.3 |
Comprehensive Income & Other | 44.78 | 33.83 | 13.73 | 0.38 | - |
Shareholders' Equity | 1,193 | 1,215 | 1,296 | 528.09 | 48.7 |
Total Liabilities & Equity | 1,278 | 1,283 | 1,350 | 540.18 | 54.12 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 23.95 | 10.9 | - | - | - |
Net Cash (Debt) | 1,008 | 1,049 | 1,215 | 524.32 | 53.97 |
Net Cash Growth | -11.05% | -13.63% | 131.67% | 871.44% | - |
Net Cash Per Share | 14.39 | 14.99 | 21.15 | 34.74 | 49.29 |
Filing Date Shares Outstanding | 70 | 70 | 70 | 70 | 1.1 |
Total Common Shares Outstanding | 70 | 70 | 70 | 45.03 | 1.1 |
Working Capital | 1,058 | 1,080 | 1,221 | 516.26 | 48.7 |
Book Value Per Share | 17.04 | 17.36 | 18.52 | 11.73 | 44.47 |
Tangible Book Value | 1,190 | 1,213 | 1,296 | 528.09 | 48.7 |
Tangible Book Value Per Share | 17.00 | 17.32 | 18.51 | 11.73 | 44.47 |
Machinery | 91.01 | 88.24 | 35.34 | 9.3 | - |
Construction In Progress | - | - | 22.6 | - | - |
Leasehold Improvements | 54.26 | 53.87 | - | - | - |